Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shares Sold by Vanguard Group Inc.

Vanguard Group Inc. lessened its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 1.7% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 22,886,162 shares of the medical equipment provider's stock after selling 398,676 shares during the period. Vanguard Group Inc. owned 11.50% of Zimmer Biomet worth $2,417,465,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also made changes to their positions in ZBH. Geode Capital Management LLC lifted its position in shares of Zimmer Biomet by 2.6% in the third quarter. Geode Capital Management LLC now owns 4,879,385 shares of the medical equipment provider's stock worth $524,942,000 after buying an additional 125,852 shares in the last quarter. Van ECK Associates Corp increased its stake in Zimmer Biomet by 5.9% in the 4th quarter. Van ECK Associates Corp now owns 3,955,449 shares of the medical equipment provider's stock worth $417,814,000 after acquiring an additional 218,688 shares during the last quarter. Hotchkis & Wiley Capital Management LLC raised its holdings in shares of Zimmer Biomet by 49.1% during the 3rd quarter. Hotchkis & Wiley Capital Management LLC now owns 1,752,298 shares of the medical equipment provider's stock worth $189,161,000 after acquiring an additional 577,320 shares in the last quarter. Equity Investment Corp boosted its position in shares of Zimmer Biomet by 57.2% during the 4th quarter. Equity Investment Corp now owns 1,021,062 shares of the medical equipment provider's stock valued at $107,855,000 after acquiring an additional 371,653 shares during the last quarter. Finally, FMR LLC grew its holdings in shares of Zimmer Biomet by 27.6% in the third quarter. FMR LLC now owns 750,336 shares of the medical equipment provider's stock valued at $80,999,000 after purchasing an additional 162,384 shares in the last quarter. Institutional investors own 88.89% of the company's stock.

Remove Ads

Insider Activity

In other news, SVP Lori Winkler sold 1,443 shares of Zimmer Biomet stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $104.40, for a total value of $150,649.20. Following the transaction, the senior vice president now directly owns 8,768 shares in the company, valued at approximately $915,379.20. This trade represents a 14.13 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Company insiders own 0.95% of the company's stock.

Analysts Set New Price Targets

ZBH has been the topic of a number of recent research reports. Truist Financial reaffirmed a "hold" rating and set a $113.00 price target (down previously from $118.00) on shares of Zimmer Biomet in a research note on Monday, February 10th. Royal Bank of Canada decreased their target price on shares of Zimmer Biomet from $130.00 to $125.00 and set an "outperform" rating on the stock in a research report on Friday, February 7th. Raymond James dropped their price target on Zimmer Biomet from $126.00 to $119.00 and set an "outperform" rating for the company in a research report on Friday, February 7th. JMP Securities restated a "market outperform" rating and set a $140.00 price objective on shares of Zimmer Biomet in a research report on Friday, February 7th. Finally, Stifel Nicolaus lifted their target price on Zimmer Biomet from $130.00 to $138.00 and gave the stock a "buy" rating in a report on Thursday, January 23rd. Two analysts have rated the stock with a sell rating, eleven have assigned a hold rating and nine have given a buy rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus target price of $124.15.

Zimmer Biomet Trading Up 0.1 %

Shares of NYSE ZBH traded up $0.06 during trading hours on Friday, reaching $112.21. The stock had a trading volume of 1,053,517 shares, compared to its average volume of 1,568,369. Zimmer Biomet Holdings, Inc. has a 52-week low of $97.69 and a 52-week high of $131.61. The firm has a market cap of $22.34 billion, a price-to-earnings ratio of 25.22, a P/E/G ratio of 1.95 and a beta of 1.04. The business's fifty day moving average price is $107.18 and its two-hundred day moving average price is $107.04. The company has a current ratio of 1.91, a quick ratio of 0.99 and a debt-to-equity ratio of 0.43.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last issued its earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share for the quarter, topping the consensus estimate of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same period in the previous year, the business posted $2.20 earnings per share. Analysts expect that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be given a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a yield of 0.86%. The ex-dividend date is Monday, March 31st. Zimmer Biomet's dividend payout ratio (DPR) is 21.57%.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.